Several tumor‐specific or associated antigens, including prostate‐specific antigen (PSA), prostate‐specific membrane antigen (PSMA), and prostate acid phosphatase (PAP), have demonstrated significant therapeutic potential in treating PCa. Here, FOLH1 is linked to posterior cortical atrophy.